Sponsored diagnostic testing programs for Hereditary ATTR Amyloidosis
Hereditary ATTR (hATTR) amyloidosis is a rare genetic condition caused by mutations in the TTR gene, leading to the buildup of misfolded transthyretin protein in nerves, the heart, and other organs. Symptoms often include progressive neuropathy, autonomic issues, and cardiomyopathy, though the presentation varies widely. Early diagnosis is important because targeted treatments are available.
5 programs found for Hereditary ATTR Amyloidosis
This sponsored program offers complimentary TTR gene testing and genetic counseling for eligible patients with suspected hereditary ATTR (hATTR) amyloidosis. It enables you to confirm or rule out the diagnosis, facilitate family risk assessment, and align patient management accordingly. All services are provided at no cost to the patient, provider, or payer.
The Invitae Unlock™ Cardiomyopathy & Arrhythmia program offers sponsored genetic testing for U.S. patients with suspected inherited cardiomyopathy or arrhythmia. The comprehensive panel supports diagnostic clarification, risk assessment, and family variant identification. The test is billed to insurance first; when a claim is denied or the patient is uninsured, the program's sponsor covers the cost of testing. Testing must be ordered by a qualified healthcare provider.
The CardioNavigATTR program is a no-charge genetic testing initiative for adult U.S. patients meeting specific criteria who are at risk for hATTR or cardiomyopathy. It offers a 36-gene cardiomyopathy panel (including TTR) to support diagnostic investigation, guide clinical decision-making, and identify hereditary risk in the cardiology setting.
The NeuroNavigATTR program offers no-cost TTR gene testing for adult U.S. patients with neuropathy or autonomic dysfunction where hATTR is part of the differential diagnosis. Neuropathic ATTR involves peripheral and autonomic nerve involvement and may mimic other hereditary or acquired neuropathies. Genetic testing helps distinguish hATTR polyneuropathy from other neuropathies and from wild-type ATTR cardiomyopathy. Testing for eligible patients
This sponsored program provides no-cost genetic testing for adult U.S. patients with a family history of hATTR, positive PYP or biopsy findings, or red-flag symptoms concerning for hATTR. Testing includes TTR gene analysis to support diagnostic evaluation, risk assessment, and clinical decision-making in patients with suspected hereditary transthyretin amyloidosis.
